Endogenous mechanisms leading to host protection and resolution of infections without immunosuppression are of wide interest 1, 2 . Here we elucidate the structures of four new host-protective molecules produced in neutrophil-endothelial cocultures and present in human and mouse tissues after sterile inflammation or infection. The bioactive molecules contain conjugated triene and diene double bonds, carry an alcohol at C13 and are derived from n-3 docosapentaenoic acid (DPA, C22:5). These compounds, termed 13-series resolvins (RvTs), demonstrated potent protective actions increasing mice survival during Escherichia coli infections. RvTs also regulated human and mouse phagocyte responses stimulating bacterial phagocytosis and regulating inflammasome components. Their biosynthesis during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 (COX-2), increased by atorvastatin via S-nitrosylation of COX-2 and reduced by COX-2 inhibitors. The actions of atorvastatin and RvTs were additive in E. coli infections in mice, where they accelerated resolution of inflammation and increased survival >60%. Taken together, these results document host-protective molecules in bacterial infections, namely RvTs, derived from n-3 DPA via transcellular biosynthesis and increased by atorvastatin. These molecules regulate key innate protective responses in the resolution of infectious inflammation.
Infections are a leading cause of mortality worldwide, with bacterial infections, including those caused by E. coli, posing an urgent health concern 1,2 . The prevalent approach for treating bacterial infections is administration of antibiotics, but with the rise in antibiotic-resistant bacteria, there is a pressing need for new treatment strategies 1, 2 . In response to infection, the host mounts inflammatory responses that, when self-resolving, are protective [3] [4] [5] . We previously characterized potent endogenous anti-inflammatory and pro-resolving mediators-namely resolvins, protectins and maresins-known as specialized pro-resolving mediators (SPMs) 4 . These are biosynthesized from n-3 essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 4 . n-3 DPA, the intermediate in DHA biosynthesis from EPA, accumulates in individuals 6 with single nucleotide polymorphisms in the gene encoding fatty acid elongase-2 and is also the precursor for new SPM families 7 .
During the resolution phase of a self-resolving acute inflammation, SPMs are produced locally and exert protective actions on leukocytes stimulating clearance of apoptotic cells, debris and bacteria and promote tissue regeneration 4, 8 . Signals produced in the early phase of infectious inflammation can determine the amplitude and duration of the inflammatory response 9 . Hence, novel mediators that may be produced during early phases of self-resolving infections to fine-tune the initial response and promote resolution are of general interest.
Neutrophils are the first line of defense against invading pathogens 10, 11 . They are rapidly recruited from the vasculature to sites of infection and participate in bacterial containment and clearance 8 . One of the first steps in recruitment is neutrophil capture onto the vascular endothelium 10 . To identify molecules that may exert host-protective actions produced during this key step, and because resolvins and protectins enhance the host clearance of bacterial infections 8 , we obtained fractions from co-incubations of these cell types using C18 solid-phase extraction (Online Methods). Given that E. coli infections are an urgent worldwide health concern, with at least ~270,000 new cases reported per year in the United States alone 12 , we next assessed the actions of these fractions in E. coli infections in mice. When administered intravenously immediately before E. coli inoculation, isolates from these human neutrophil-endothelial cell co-incubations significantly enhanced survival from lethal E. coli infections ( Fig. 1a ; P < 0.05) and did not display direct classic antibacterial activity (Supplementary Fig. 1a) .
To characterize and elucidate bioactive molecules within these fractions and deduce their structures, we initially used liquid chromatography tandem mass-spectrometry (LC-MS-MS)-based lipid mediator (LM) metabololipidomics. Along with classic eicosanoids and SPMs, we identified previously unknown molecules in the bioactive fractions that showed activity from neutrophilendothelial cell co-incubations. These gave four distinct MS-MS spectra and retention times characteristic of a 22-carbon backbone with five double bonds, suggesting DPA was the precursor 7 . Using MS-MS fragmentations we deduced the structures of these new n-3 DPA-derived bioactive molecules as 7,13,20-trihydroxydocosapentaenoic acid; 7,12,13-trihydroxy-docosapentaenoic acid; 7,8,13-trihydroxy-docosapentaenoic acid; and 7,13-dihydroxydocosapentaenoic acid (Fig. 1b and Supplementary Figs. 1b  and 2a-d) . We confirmed their assignments using physical characteristics, including MS-MS of different chemical derivatives and reactivity (i.e., molecular oxygen ( 18 O 2 ) incorporation, acid methanol trapping and methyl ester; see below and Online Methods) for each product. Co-incubations of neutrophil-endothelial cells with n-3 DPA but not DHA nor EPA precursors to SPMs 4,9 increased their amounts 30-50% (Supplementary Fig. 2e ). Thus these new bioactive structures were denoted RvT1, RvT2, RvT3 and RvT4, respectively, as each carried a C13 alcohol from their biosynthetic origin ( Fig. 1b  and Supplementary Fig. 1b) .
Because exercise in humans leads to a self-resolving inflammatory state marked by increases in plasma lipid mediators 13 , we investigated RvT production in healthy volunteers during exercise. We observed significant increases (P < 0.05) in peripheral blood RvTs, as compared to pre-exercise levels ( Fig. 1c and Supplementary Table 1a,b) . Their amounts were comparable in magnitude to those from the arachidonic acid (AA), EPA or DHA bioactive-metabolomes, namely prostaglandins, leukotriene B 4 , resolvins, protectins and maresins (Supplementary Table 1b) . RvTs were also identified in human peripheral blood from sepsis patients and their amounts were higher ( Fig. 1d and Supplementary Table 2 ) when compared to amounts in plasma from healthy volunteers and those in a human plasma composite obtained from the National Institutes for Standards and Technologies (SRM1950). Resolvins and lipoxins were also increased in plasma from sepsis patients when compared to plasma from healthy volunteers and the SRM1950 plasma composite (Supplementary Table 2b) .
We then assessed the temporal regulation of RvTs during bacterial infections in mice. Friend leukemia virus B (FVB) mice challenged with E. coli (10 5 colony-forming units (c.f.u.) E. coli per mouse) had a self-resolving (i.e., self-limited) inflammatory response, with polymorphonuclear leukocyte (PMN) numbers reaching a maximum at ~12 h after inoculation and declining thereafter 8 . RvTs were rapidly formed during the initiation phase of inflammation, with amounts in peripheral blood reaching a maximum at 4 h and subsequently declining (Fig. 1e) . By comparison, mediators derived from AA-, EPA-and DHA-derived metabolomes began to increase at 4 h with the majority reaching their maximum at 12 h. These included RvD2 and LXB 4 (Supplementary Table 3) . Notably, RvTs were >60% lower in peripheral blood from mice challenged with a higher E. coli burden that was nonlethal but caused increased inflammation with delayed resolution (10 7 c.f.u. per mouse; Fig. 1f and Supplementary Table 4) .
We speculated on the basis of human neutrophil-endothelial cell co-incubations that RvTs were products of transcellular biosynthesis because these co-incubations gave appreciable amounts of RvT1, RvT2, RvT3 and RvT4 (Supplementary Fig. 2f ). Chiral LC-MS-MS demonstrated that endothelial cells incubated with n-3 DPA produced more 13R-hydroxy-7Z,10Z,14,16Z,19Z-docosapentaenoic acid (13R-HDPA; Supplementary Fig. 3a-d ) than did cells kept in culture medium alone. Because interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) upregulate expression of endothelial COX-2 (ref. 14) , which converts DHA to 13-HDHA 9 , we questioned whether endothelial COX-2 also converts n-3 DPA to produce 13-HDPA. Incubation of endothelial cells with the COX-2 selective inhibitor celecoxib or transfection of endothelial cells with small hairpin RNA (shRNA) targeting COX-2 led to significant (P < 0.05) reductions in endothelial cell-derived 13-HDPA (Supplementary Fig. 3e,f) , indicating a role for COX-2 in 13-HDPA production. Incubations of n-3 DPA with human recombinant COX-2 gave 13R-HDPA with K M = 3.1 ± 1.3 µM (mean ± s.e.m.)( Supplementary Fig. 3g,h ), suggesting that n-3 DPA is converted to 13R-hydroperoxydocosapentaenoic acid by endothelial COX-2. This intermediate or its reduced alcohol form may then be donated to neutrophils that convert the intermediate(s) to RvTs. This proposed biosynthetic route and the RvT structures were corroborated by assessing ultraviolet (UV) chromophores, MS-MS fragmentation spectra for methyl-ester derivatives ( Supplementary Fig. 4 ), 18 O 2 incorporation (Supplementary Fig. 5 ) and acid-alcohol trapping of epoxide intermediates ( Supplementary  Fig. 6 ). These results indicate that COX-2-derived 13-HDPA is converted via lipoxygenation in human neutrophils to RvT1, RvT2, RvT3 and RvT4.
Because atorvastatin is protective in bacterial infections in mice 15 and regulates COX-2 (ref. 16 ), we wondered whether this statin Table 5 ). Fractions from these co-incubations were administered to mice immediately prior to E. coli and significantly increased survival when compared to fractions from neutrophil-endothelial cell cocultures without atorvastatin ( Fig. 2b ; P < 0.05) and those from neutrophils or endothelial cells incubated separately with atorvastatin ( Fig. 2b) . Celecoxib significantly reduced the amounts of RvTs in these incubations ( Fig. 2c ; P < 0.05) and abolished the protective actions of isolated fractions obtained from neutrophil-endothelial cell co-incubations with atorvastatin ( Fig. 2d) . Administration of l-NG-nitroarginine methyl ester (l-NAME) before atorvastatin significantly reversed atorvastatin-mediated increases in plasma RvT ( Fig. 2e ; P < 0.05) and increased neutrophil recruitment to the peritoneum during mouse infections (Fig. 2f) . With human endothelial cells, nitric oxide synthase inhibitors (l-NAME and 1400W) also significantly reduced atorvastatinmediated RvT increases by 70-90% (Supplementary Fig. 7a ; P < 0.05). In addition, incubation of human recombinant COX-2 (hrCOX-2) with S-nitrosoglutathione, which S-nitrosylates COX-2 (ref. 18) (Supplementary Fig. 7b ), led to increased 13R-HDPA and hrCOX-2 catalytic activity ( Fig. 2g ) compared to native COX-2. These results indicated that atorvastatin increased RvT production via S-nitrosylation of endothelial COX-2.
We then tested the bioactions of these molecules with human leukocytes. We produced RvTs using recombinant enzymes and primary human neutrophils and isolated them using reverse phase high-pressure liquid chromatography (RP-HPLC; Online Methods). RvT1 and RvT4 were isolated to apparent homogeneity on the basis of their appearance beneath a single RP-HPLC peak and characteristic UV chromophores. RvT2 and RvT3 were tested together because they eluted in the same RP-HPLC fractions. RvT1 (1 pM-10 nM ) dose-dependently increased E. coli phagocytosis and production of intracellular reactive oxygen species (ROS) in human macrophages (Fig. 3a,b) as well as efferocytosis of apoptotic neutrophils (Fig. 3c) , a key step in the resolution of inflammation 4 . Similar actions were observed with human neutrophils, where RvT1 (1 pM-10 nM) dose-dependently increased E. coli phagocytosis (20-55%) and intracellular ROS levels (20-40%; n = 4 donors). RvT1 (10 pM-10 nM) also dose-dependently blocked human macrophage activation of inflammasome components, decreasing caspase-1 and IL-1β expression and extracellular lactate dehydrogenase (LDH) activity ( Supplementary Fig. 8a-c) . Similar results were obtained with RvT4 and ~1:1 mix of RvT2 and RvT3 ( Supplementary Fig. 8a-c) .
Given that RvTs were identified in human and murine infections, we assessed their combined actions in E. coli infections in mice, administering a mixture of RvT1, RvT2, RvT3 and RvT4 (RvT1-4) immediately before intraperitoneal E. coli inoculation. Twelve hours later these molecules afforded dose-dependent protection against hypothermia, limited further neutrophil recruitment to sites of inflammation, increased bacterial phagocytosis by peritoneal leukocytes (Fig. 3d-f ) and reduced monocyte and macrophage expression of caspase-1, IL-1β levels and LDH activity ( Supplementary  Fig. 8d -f) without exerting bactericidal or bacteriostatic actions ( Supplementary Fig. 9a ). RvTs also reduced systemic inflammation, as demonstrated by reduced platelet-leukocyte aggregates 7 ( Supplementary Fig. 8g ). LM metabololipidomics of plasma from mice given RvT1-4 (500 ng per mouse) showed significant reductions in TxB 2 , prostaglandin (PG) D 2 and PGE 2 (Supplementary Fig. 9b ; P < 0.05), which are elevated by inflammasome activation (i.e., eicosanoid storm) during infection 19 . RvTs also significantly increased exudate macrophage efferocytosis ( Fig. 3g ; P < 0.05). Moreover, RvT3 RvT4 npg l e t t e r s 1 0 7 4 VOLUME 21 | NUMBER 9 | SEPTEMBER 2015 nature medicine administration of RvT1-4 2 h after E. coli inoculation dosedependently increased mice survival (Fig. 3h) . Prolonged statin use is linked to a number of adverse effects, including inflammasome activation 20 and diabetes 21 . Therefore, we next tested whether RvTs could reduce the effective dose of atorvastatin needed to clear E. coli infections and, thus, reduce statin exposure. Coadministration of RvT1, RvT2, RvT3 and RvT4 (~12.5 ng each per mouse) and a subthreshold dose of atorvastatin (0.5 µg per mouse) immediately before E. coli inoculation protected mice from hypothermia and significantly (P < 0.05) reduced neutrophil recruitment (~50%), local and systemic bacterial loads, exudate IL-1β levels (~45%) and LDH activity (~40%; Supplementary Fig. 10a-e ) when compared to mice administered E. coli and vehicle. This treatment also significantly increased bacterial phagocytosis by exudate leukocytes (~90%) and efferocytosis by exudate macrophages (~90%; Supplementary Fig. 10f,g ; P < 0.05). These results suggest that RvTs may reduce exposure to atorvastatin therapy, potentially limiting some of the unwanted side effects observed with higher statin doses 20, 21 .
To assess whether this treatment regime was protective in a therapeutic setting, we treated mice with atorvastatin (0.5 µg per mouse) Data are mean ± s.e.m. n = 4 mice per group from two independent experiments. **P < 0.01 vs. exudates collected from mice administered E. coli and vehicle 24h after inoculation. Ψ max = maximal PMN numbers in exudates; T max = time point when PMN numbers reach maximum; R 50 = 50% of maximal PMN numbers; T 50 = time point when PMN numbers reduce to 50% of maximum; R i (resolution interval) = T 50 -T max , time period when 50% PMN are lost from the exudates. (b) Survival in mice after inoculation with E. coli (2.5 × 10 7 c.f.u. per mouse) and administration of vehicle (saline + 0.1% ethanol), low-dose atorvastatin (0.5 µg per mouse), high-dose atorvastatin (5 µg per mouse), low-dose atorvastatin plus low-dose RvT (50 ng per mouse) or high-dose atorvastatin plus high-dose RvT (500 ng per mouse) (RvTs were isolated as in a). n = 10 mice per group from three independent experiments. *P < 0.05, **P < 0.01 vs. E. coli. #P < 0.05 vs. E. coli plus low-dose atorvastatin. Atorv, atorvastatin. and/or the RvT1-4 mix (50 ng per mouse) 2 h after E. coli inoculation. Administration of atorvastatin together with RvT significantly reduced neutrophil recruitment to the peritoneum and reduced exudate bacterial loads (Supplementary Fig. 10h ; P < 0.05). To gain insight into potential mechanisms activated by atorvastatin and RvTs, we investigated expression of host-protective 22, 23 and pro-inflammatory factors 24 regulated by atorvastatin. In mice given 0.5 µg statin alone, we measured increases in host-protective prostacyclin (PGI 2 ) and 15-deoxy-∆-12,14 -PGJ 2 ( Supplementary Fig. 10i ), whereas it decreased endothelin-1 and plasminogen activator inhibitor-1, molecules associated with a proinflammatory status (Supplementary Fig. 10j ).
RvT administration (50 ng per mouse) regulated some of these molecules, although to a lesser extent (~30-60% lower) than atorvastatin ( Supplementary Fig. 10i,j) . Administration of atorvastatin with RvT1-4 significantly decreased endothelin-1 and plasminogen activator inhibitor-1 expression in comparison to vehicle or RvT alone ( Supplementary Fig. 10j,k ; P < 0.05). Peripheral blood eicosanoids were also reduced upon RvT1-4 administration (Supplementary Fig. 10k ), effects that were only partly shared with atorvastatin, because statin administration did not markedly decrease peripheral blood PGE 2 .
Given these protective actions, we assessed whether administration of RvT together with atorvastatin could accelerate resolution of infections. Administration of RvT1-4 (50 ng per mouse) with atorvastatin (0.5 µg per mouse) at peak neutrophil infiltration (12 h) significantly accelerated exudate neutrophil clearance, increased bacterial phagocytosis by exudate leukocytes (~50%; P < 0.05) and accelerated resolution of inflammation, shortening the resolution interval from ~20 h to ~8 h (Fig. 4a) . Treatment of mice with RvT1-4 and atorvastatin at high (500 ng of RvT1-4 and 5 µg atorvastatin) or low (50 ng RvT and 0.5 µg atorvastatin) doses increased the percentage that survived longer when compared to those treated with atorvastatin alone (Fig. 4b) . Together these results suggest that during infection, RvTs lower the effective dose of atorvastatin.
In summary, we have used LC-MS-MS-based lipid mediatormetabololipidomidics to elucidate the structures of four new bioactive molecules, termed RvTs, formed by transcellular biosynthesis 4,9,14 during human neutrophil-endothelial cell interactions (Supplementary Table 6 and Supplementary Fig. 1b) . RvT production was increased during self-resolving inflammatory challenge in humans and mice and downregulated in mice during delayed resolution of infections. These RvTs from n-3 DPA exerted both anti-inflammatory and potent pro-resolving activities regulating host responses during E. coli infection in mice and phagocytosis by isolated human cells, thereby fulfilling criteria as immunoresolvents 4 , as would their 13-HDHA forms-namely, they stimulate the cardinal signs of resolution, including clearance of debris (expurgatio reliquiorum), clearance of infective agents (expurgatio contagionem agentis), analgesia (doloris absentia) and gain of function (muneris lucrum) 4 . Given the extensive size of the vascular-endothelial system in humans and the abundance of neutrophils within the circulation, formation of RvTs during early stages of self-resolving acute inflammation and their regulation by atorvastatin could provide a molecular basis for the development of new treatment strategies for infectious inflammation. In addition, RvTs may also serve as markers and mediators of statin actions during resolution responses.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
E. coli peritonitis. Animals. All animal experiments were conducted in accordance with the Harvard Medical Area Standing Committee on Animals (protocol 02570). Mice (male Friend leukemia virus B, 6-8 weeks old, Charles River, fed lab diet containing essential fatty acids as from supplier) were anesthetized with isoflurane and microbial peritonitis initiated. Briefly, test compounds or vehicle were injected intraperitoneally (i.p.) or intravenously (i.v.) 5 min before injection of live E. coli (serotype O6:K2:H1; 1 × 10 5 or 1 × 10 7 c.f.u. per mouse). At designated time intervals mice were euthanized, blood was collected via cardiac puncture in heparin and peritoneal exudates were collected in 4 ml PBS.
The cellular composition in the exudates was determined using Turks solution and light microscopy, and by flow cytometry. For flow cytometry, exudate cells were incubated with anti-mouse CD16/CD32 (eBiosciences, clone 93, dilution 1:100, 20 min, 4 °C, in PBS containing 5% FCS-staining solution), followed by incubation with FITC-conjugated anti-mouse Ly6G antibody (clone 1A8, dilution 1:100, eBiosciences), PE-conjugated anti-mouse F4/80 antibody (clone BM8 dilution 1:50, eBiosciences) and PerCP-Cy5.5-conjugated anti-mouse CD11b antibody (clone M1/70, dilution 1:100, eBiosciences) for 30 min (4 °C, in staining solution).
To assess bacterial phagocytosis in peritoneal exudate leukocytes, exudate cells were incubated with PerCP-Cy5.5-conjugated anti-mouse CD11b antibody (30 min, 4 °C, in staining solution), then fixed and permeabilized using BD Perm/Wash Buffer (BD Biosciences) following manufacturer's instructions and incubated with FITC-conjugated anti-E. coli antibody (GenTex, cat. no. GTX13626, dilution 1:50, 30 min, 4 °C, in BD Perm/Wash Buffer).
Efferocytosis in infectious exudates was assessed by incubating exudate leukocytes with PE-conjugated anti-mouse F4/80 antibody (30 min, 4 °C, in staining solution), then fixed and permeabilized using BD Perm/Wash Buffer (BD Biosciences) and incubated with FITC-conjugated anti-mouse Ly6G antibody (30 min, 4 °C, in BD Perm/Wash Buffer). Body temperatures were assessed using an infrared thermometer (Fluke). Bacterial counts in peripheral blood and inflammatory exudates were determined by overnight cultures (37 °C) of serially diluted samples on LB agar plates. Caspase 1 levels were assessed by incubation of exudate cells with PerCP-Cy5.5-conjugated anti-mouse CD11b antibody (30 min, 4 °C, in staining solution), then fixed and permeabilized using BD Perm/Wash Buffer (BD Biosciences), incubated with anti-caspase 1 antibody (Abcam, cat. no. ab108302, dilution 1:100, 30 min, 4 °C, in BD Perm/Wash Buffer) followed by anti-rabbit Alexa 488-conjugated antibody (Life Technologies, cat. no. A11034, 30 min, 4 °C, in BD Perm/Wash Buffer). IL-1β levels were determined in cell-free supernatants using an antimouse IL-1β ELISA (Abcam) following the manufacturer's instructions. Lactate dehydrogenase activity was measured in cell-free supernatants assessing the formation of NADH from NAD + using a Lactate Dehydrogenase Assay kit (Sigma) following manufacturer's instructions.
In select experiments resolution indices were calculated as described previously 25 , where Ψ max = maximal PMN numbers in exudates; T max = time point when PMN numbers reach maximum; R 50 = 50% of maximal PMN numbers; T 50 = time point when PMN numbers reduce to 50% of maximum; R i (resolution interval) = T 50 -T max , time period when 50% PMN are lost from the exudates. To assess the pro-resolving actions of the test products, these were administered 12 h after E. coli (10 5 c.f.u.) inoculation, and resolution indices were assessed.
To determine the regulation of lung endothelin-1 and plasminogen activator inhibitor-1 as well as peripheral blood eicosanoids by RvTs and atorvastatin, mice were administered via i.p. injection RvT1, RvT2, RvT3 and RvT4 (isolated as detailed below and combined as a mixture at a ratio of 2:1:1:8, respectively 50 ng total), 0.5 µg atorvastatin or a RvT1-4 and atorvastatin 2 h after E. coli inoculation. Blood and lungs were harvested 6 h after E. coli inoculation. Blood was employed to determine peripheral blood eicosanoid levels as detailed below. Lungs were placed in TriReagent (Invitrogen), RNA isolated following manufacturer's instructions and relative mRNA expression for mouse endothelin-1 and plasminogen activator inhibitor-1 determined using Qiagen SYBR Green ROX qPCR mastermix and QuantiTect Primer assays following manufacturer's instruction and using mouse Gapdh as a housekeeping gene. mRNA expression was determined using an ABI PRISM 7900HT system (Applied Biosystems). In determined experiments, peritoneal exudates were obtained from mice 12 h after E. coli inoculation and bacterial loads along with leukocyte counts determined as detailed above.
For survival studies, mice were administered test compounds or biological isolates from neutrophil-endothelial cell (HUVEC) co-incubations via i.p. injection 5 min before inoculation with E. coli (2.5 × 10 7 c.f.u.), and survival was assessed. In designated experiments, RvT1, RvT2, RvT3 and RvT4 were isolated as detailed below, combined as a mixture at a ratio of 2:1:1:8 respectively, and were administered via i.p. injection 2 h after E. coli (2.5 × 10 7 c.f.u.); survival was assessed for the subsequent 94 h. In separate experiments, 0.5 µg (lower dose) or 5 µg (higher dose) of atorvastatin was administered via i.p. with or without RvT1, RvT2, RvT3 and RvT4, which were isolated and quantified as detailed below, combined as a mixture (at a ratio of 2:1:1:8) at the indicated concentrations 3 h after E. coli (2.5 × 10 7 c.f.u.) inoculation, and survival assessed for the next 93 h.
In a separate set of experiments, mice were inoculated with E. coli; after 60 min they were given l-NAME (24 mg/kg) and 5 min later atorvastatin (5 µg) via i.v. injection. Plasma was obtained after 5 h via cardiac puncture and LM levels were investigated by lipid mediator metabololipidomics. For all animal experiments mice were randomized to vehicle or treatment groups without blinding.
Biosynthesis and lipid mediator metabololipidomics. Isolated n-3 DPA (Cayman Chemicals) was incubated with human recombinant COX-2 (Cayman Chemicals; in 0.1 M Tris-HCl, pH 8.0, 20 µM porcine hematin, 0.67 mM phenol) for 30 min at room temperature (RT). Incubations were stopped with 1 volume of methanol and products extracted using diethyl ether as described 26 . 13-HDPA was isolated using RP-HPLC (1100 Series; Agilent Technologies) and an Agilent C18 Poroshell column (2.7 µm × 4.6 mm × 150 mm) with a mobile phase consisting of methanol/water (60:40, vol/vol) at 0.5 ml/min that was ramped up to 98:2 (vol/vol) for 20 min. 13-HDPA (10 µM) was incubated with potato 5-LOX (Cayman Chemicals) for 30 min (4 °C, 0.1 M phosphate buffer, pH 6.3, 0.03% Tween 20) . Incubations were stopped with 1 volume of ice-cold methanol, and products were reduced using NaBH 4 (Sigma-Aldrich) and extracted as described 26 .
Methanol (two volumes) was added to cell incubations, plasma (mouse and human) and infectious exudates, and samples stored at −20 °C until extraction. All samples for LC-MS-MS-based metabololipidomics were extracted with solid-phase extraction columns as previously reported 27 . Prior to sample extraction, deuterated internal standards (d 4 To monitor and quantify the levels of lipid mediators, a multiple reaction monitoring (MRM) method was developed with signature ion fragments (m/z) for each molecule monitoring the parent ion (Q1) and a characteristic daughter ion (Q3). Identification was conducted using published criteria where a minimum of 6 diagnostic ions were employed 27 . Calibration curves were determined using a mixture of lipid mediators obtained via total organic synthesis, where these lipid mediators were not available (RvT1, RvT2, RvT3, RvT4 and 13-HDPA); known mediators with similar chromatographic properties (RvD2 for RvT1, RvD1 for RvT2 and RvT3; RvD5 for RvT4; 13-HDHA for 13-HDPA) were used. Linear calibration curve for each compound was obtained with r 2 values ranging from 0.98 to 0.99. Detection limit was ~0.1 pg. Quantification was carried out as described 27 . To measure 6-keto-PGF 1α levels, samples were extracted as outlined above, suspended in water and 6-keto-PGF 1α levels measured using a 6-keto-PGF 1α ELISA (Neogen).
For chiral lipidomic analysis, a Chiralpak AD-RH column (150 mm × 2.1 mm × 5 µm) was used with isocratic methanol/water/acetic acid 95:5:0.01 (v/v/v) at 0.15 ml/min. To monitor isobaric monohydroxy docosapentaenoic acid levels, npg a multiple reaction monitoring (MRM) method was developed using signature ion fragments for each molecule as described 28 .
In select experiments, RvT1, RvT2, RvT3 and RvT4 were incubated with diazomethane in ether, prepared as described 26 for 30 min at 37 °C and products assessed by LC-MS-MS, operating the mass spectrometer in positive ion mode.
In order to extract products from neutrophil-endothelial cell co-incubations for biological evaluation, two volumes of ice-cold methanol were added to stop the incubations and the samples placed at −20 °C for at least 30 min to allow for protein precipitation. Products were then extracted using C18 SPE as detailed above and eluted using methyl formate. The solvent was then evaporated under nitrogen and products suspended in ethanol for biological evaluation.
13R-HDPA and 13S-HDPA were obtained by incubating 13-HDPA with Dess Martin Periodinane (0.03 M in methylene chloride, 30 min, RT); the resulting 13-oxo-DPA was then incubated with either (R)-2-methyl-CBS-oxazaborolidine or (S)-2-methyl-CBS-oxazaborolidine as described 29 .
In some experiments, human peripheral neutrophils (5 × 10 7 cells/ml) were incubated with 13R-HDPA (1 µM, 37 °C, PBS pH 7.45) and E. coli (1 × 10 9 c.f.u./ml, 2 min, 37 °C). Incubations were stopped with two volumes of acidified methanol (apparent pH 3), products extracted and profiled using LM metabololipidomics.
Human neutrophils (4 × 10 7 cells/ml) were incubated with 13R-HDPA (300 nM) in PBS (pH 7.45, 37 °C) in an 18 O 2 enriched environment; E. coli (2 × 10 9 c.f.u./ml) were then added. The incubations were quenched after 30 min using two volumes of ice-cold methanol, then incubated with sodium borohydride (1 µg/ml, 15 min, 4 °C), products extracted and profiled using LM metabololipidomics. The following MRM transitions were used to monitor each of the new products: RvT1-381 > 145, RvT2-379 > 145, RvT3-379 > 227 and RvT4-363 > 145.
Whole blood from healthy volunteers (HV) self-reported to exercise for at least 45 min 2-3 times per week and to have taken no medications including nonsteroidal anti-inflammatory drugs, ASA-containing products or statins 10-14 d before venipuncture (Partners Human Research Committee Protocol 1999P001297), was obtained with written consent in accordance with the Declaration of Helsinki and Partners Human Research Committee Protocol 1999P001279 for discarded materials (CNS). Participants rested for 5-10 min in a seated position before preexercise peripheral blood sampling. The exercise protocol commenced immediately after sampling, involving 10 min warming up and stretching exercises followed by 30-45 min of vigorous intensity continuous cycling or cross-training. terminating when subjects reached ~90% of their theoretical maximum. This was calculated using the formula 220 − age in years as described 30 . Blood was collected from these subjects within 15 min of exercise termination. All blood samples were collected in heparin, then placed in four volumes of ice-cold methanol containing internal standards, and mediator levels were assessed by LC-MS-MS as detailed above.
Plasma from patients diagnosed with sepsis was obtained from Dx Biosamples (see Supplementary Table 2 for demographics). Plasma from healthy volunteers (HV) was collected as outlined above. Human reference plasma denoted SRM 1950 was purchased from the National Institute of Standards and Technology (NIST). Plasma from these patients and volunteers was placed in two volumes of ice-cold methanol containing internal standards, and mediator levels assessed by LC-MS-MS as detailed above.
Whole blood was collected in heparin at determined time intervals during E. coli infections in mice. This was then placed in four volumes of ice-cold methanol containing internal standards, and mediator levels assessed by LC-MS-MS as detailed above.
Neutrophil-endothelial co-incubations. Human umbilical endothelial cells (HUVEC; 8.5 × 10 5 cells/9.6cm 2 ) were incubated with IL-1β (10 ng/ml) and TNF-α (10 ng/ml; 16 h, 37 °C, 5% CO 2 ). Cells were then incubated with atorvastatin (30 nM-30 µM), celecoxib (25 µM), l-NAME (25 µM), 1400 W (10 µM) or vehicle (PBS containing 0.01% DMSO) followed by addition of n-3 DPA (1 µM, 1 h, 37 °C, 5% CO 2 ). In select experiments, 30 min after n-3 DPA addition, human neutrophils (1 × 10 7 cells/ml) were added and cells incubated for 60 min (37 °C, 5% CO 2 ). Incubations were stopped with two volumes of ice-cold methanol and products extracted as detailed above. In determined experiments after the addition of human PMN, E. coli (5 × 10 8 c.f.u./ml) were also added and cells incubated 60 min (37 °C, 5% CO 2 ). Incubations were then stopped with two volumes ice-cold methanol and LM profiles assessed using LM-metabololipidomics.
Endothelial cells were transfected with control scrambled shRNA or human COX-2 shRNA (Origene) using jetPEI-HUVEC (PolyPlus) following manufacturer's instructions, and then incubated with IL-1β (10 ng/ml) and TNF-α (10 ng/ml; 16 h, 37 °C, 5% CO 2 ). Cells were then incubated with n-3 DPA (1 µM, 37 °C, 5% CO 2 , in 0.1% EGM). Incubations were stopped with two volumes of ice-cold methanol and lipid mediators assessed by lipid mediator metabololipidomics.
Human neutrophil and macrophage phagocytosis and ROS. Macrophages were prepared from peripheral blood mononuclear cells (PBMC) purchased from Children's Hospital Blood Bank, Boston, and phagocytosis was assessed as described 29 . Briefly, macrophages (5 × 10 4 cells per well) were incubated with RvT1 (1 pM-10 nM ), 1:1 mixture RvT2 and RvT3 (1 pM-10 nM ), RvT4 (1 pM-10 nM) or vehicle (0.1% ethanol in DPBS) for 15 min at 37 °C, then fluorescent labeled apoptotic cells were added and cells incubated 45 min at 37 °C. Extracellular fluorescence was quenched using Trypan blue (1:15 dilution) and phagocytosis assessed using an M3 SpectraMax plate reader (Molecular Devices). In select experiments, macrophages (prepared as detailed above, 5 × 10 4 cells per well) or neutrophils (1 × 10 5 cells per well), obtained from human healthy volunteers and isolated as described 29 Caspase 1 levels were assessed in macrophages by flow cytometry after cell fixing and permeabilization, staining with an anti-caspase 1 (Abcam; 4 °C, 30 min) and anti-rabbit-Alexa 488-conjugated antibody (Molecular Probes; 4 °C, 30min). IL-1β levels were determined in cell-free supernatants using an anti-human IL-1β ELISA (eBiosciences) following the manufacturer's instructions.
Lactate dehydrogenase activity was measured in cell-free supernatants assessing the formation of NADH from NAD + using a Lactate Dehydrogenase Assay kit (Sigma) following manufacturer's instructions.
Recombinant enzyme incubations.
Human recombinant COX-2 (10 units; Cayman Chemicals; in 0.1 M Tris-HCl, pH 8.0, 20 µM porcine hematin, 0.67 mM phenol) 31 was incubated with the indicated concentrations of AA or n-3 DPA (1h, RT) and absorbance at 235 nM was investigated at 1 min intervals using a Cary UV-Vis Spectrophotometer (Agilent).
In designated experiments, n-3 DPA was incubated with hrCOX2 as well as hrCOX-2 that was previously incubated with S-nitrosoglutathione (30 min RT), prepared by incubating 100 mM glutathione with 100 mM sodium nitrite in npg
